S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
105. Qian J, Wollan P, Bostwick DG. The extent and multicentricity of high-grade prostatic
intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol
1997;28(2):143-8. http://www.ncbi.nlm.nih.gov/pubmed/9023393
106. Keetch DW, Humphrey P, Stahl D, Smith DS, Catalona WJ. Morphometric analysis and clinical
followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate.
Journal of Urology 1995;154(2 Pt 1):347-51.
http://www.ncbi.nlm.nih.gov/pubmed/7541850
107. Epstein JI. PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North
Am 1993;20(4):757-70. http://www.ncbi.nlm.nih.gov/pubmed/7505984
108. Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, Chang C, Loda M.
Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol
1997;10(8):839-45. http://www.ncbi.nlm.nih.gov/pubmed/9267828
109. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue
localization and diagnostic utility of prostate specific membrane antigen. Cancer
1998;83(11):2259-69. http://www.ncbi.nlm.nih.gov/pubmed/9840525
110. Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, Grignon DJ,
Fanger GR, Amin MB. P504S immunohistochemical detection in 405 prostatic specimens
including 376 18-gauge needle biopsies. Am J Surg Pathol 2002;26(12):1588-96.
http://www.ncbi.nlm.nih.gov/pubmed/12459625
111. Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural patterns of highgrade
prostatic intraepithelial neoplasia. Hum Pathol 1993;24(3):298-310.
http://www.ncbi.nlm.nih.gov/pubmed/8454275
112. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol
2004;17(3):360-79. http://www.ncbi.nlm.nih.gov/pubmed/14739906
113. Helpap B, Bocking A, Dhom G, Faul P, Kastendieck H, Leistenschneider W, Muller HA.
Klassifikation, histologisches und zytologisches Grading sowie Regressionsgrading des
Prostatakarzinoms. Der Urologe Ausg A 1985;24(3):156-9.
http://www.ncbi.nlm.nih.gov/pubmed/4012943
114. Helpap B. Prognosefaktoren des Prostatakarzinoms. Pathologe 1998;19(1):42-52.
http://www.ncbi.nlm.nih.gov/pubmed/9541941
115. Mostofi FK. Hystological typing of prostate tumours. In: Mostofi FK, editor. WHO
international histological classification of tumours. 2nd ed. Berlin: Springer; 2002. p. 15-6
116. Helpap B, Egevad L. Modified Gleason grading. An updated review. Histol Histopathol
2009;24(5):661-6. http://www.ncbi.nlm.nih.gov/pubmed/19283673
117. Renshaw AA. Adequate tissue sampling of prostate core needle biopsies. Am J Clin Pathol
1997;107(1):26-9. http://www.ncbi.nlm.nih.gov/pubmed/8980363
118. Brat DJ, Wills ML, Lecksell KL, Epstein JI. How often are diagnostic features missed with less
extensive histologic sampling of prostate needle biopsy specimens? Am J Surg Pathol
1999;23(3):257-62. http://www.ncbi.nlm.nih.gov/pubmed/10078914
119. Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Newling D, Nilsson S,
Sakr W, Srigley JR, Wheeler TM, Montironi R. Prognostic and predictive factors and reporting
of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl
2005;(216):20-33. http://www.ncbi.nlm.nih.gov/pubmed/16019757
120. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with
cancer is more predictive of biochemical failure or adverse pathology after radical
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011